Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities

IF 4.5 2区 医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-10-22 DOI:10.1016/j.lungcan.2024.107994
Xue He , Zhihui Yang , Fang Wu , Qingchun Liang , Wenliang Liu , Fenglei Yu , Chen Chen
{"title":"Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities","authors":"Xue He ,&nbsp;Zhihui Yang ,&nbsp;Fang Wu ,&nbsp;Qingchun Liang ,&nbsp;Wenliang Liu ,&nbsp;Fenglei Yu ,&nbsp;Chen Chen","doi":"10.1016/j.lungcan.2024.107994","DOIUrl":null,"url":null,"abstract":"<div><div>The increased detection of synchronous multiple primary lung cancers (sMPLC) through advanced computed tomography underscores the necessity for innovative therapeutic approaches. sMPLC typically manifests as ground-glass opacities, mixed ground-glass opacities, and/or solid nodules, predominantly in early-stage, non-smoking female patients, with a majority being adenocarcinomas. The high prevalence of EGFR mutations and considerable heterogeneity among lesions pose distinct diagnostic and therapeutic challenges for sMPLC. This study provides a comprehensive review and analysis of recent clinical and radiological studies, genomic profiling, and the efficacy of the “Surgery + X” treatment model for sMPLC. Additionally, the article discusses several intricate and complex sMPLC cases, shedding light on the disease’s complexities and identifying existing gaps and potential breakthroughs in clinical diagnosis, treatment, and research. It underscores the critical role of a multidisciplinary approach and advocates for targeted research on sMPLC, highlighting its potential to impact lung cancer research significantly.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"197 ","pages":"Article 107994"},"PeriodicalIF":4.5000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224005282","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The increased detection of synchronous multiple primary lung cancers (sMPLC) through advanced computed tomography underscores the necessity for innovative therapeutic approaches. sMPLC typically manifests as ground-glass opacities, mixed ground-glass opacities, and/or solid nodules, predominantly in early-stage, non-smoking female patients, with a majority being adenocarcinomas. The high prevalence of EGFR mutations and considerable heterogeneity among lesions pose distinct diagnostic and therapeutic challenges for sMPLC. This study provides a comprehensive review and analysis of recent clinical and radiological studies, genomic profiling, and the efficacy of the “Surgery + X” treatment model for sMPLC. Additionally, the article discusses several intricate and complex sMPLC cases, shedding light on the disease’s complexities and identifying existing gaps and potential breakthroughs in clinical diagnosis, treatment, and research. It underscores the critical role of a multidisciplinary approach and advocates for targeted research on sMPLC, highlighting its potential to impact lung cancer research significantly.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
面对同步多发性原发性肺癌:挑战与机遇并存。
同步多发性原发性肺癌(sMPLC)通过先进的计算机断层扫描发现的病例越来越多,这凸显了创新治疗方法的必要性。sMPLC通常表现为磨玻璃不透明、混合磨玻璃不透明和/或实性结节,主要发生在早期非吸烟女性患者中,其中大多数为腺癌。表皮生长因子受体(EGFR)突变的高发生率和病变间的显著异质性为sMPLC的诊断和治疗带来了独特的挑战。本研究全面回顾和分析了最近的临床和放射学研究、基因组剖析以及 "手术+X "治疗模式对sMPLC的疗效。此外,文章还讨论了几个错综复杂的 sMPLC 病例,揭示了该疾病的复杂性,找出了临床诊断、治疗和研究方面的现有差距和潜在突破。文章强调了多学科方法的关键作用,并倡导对sMPLC进行有针对性的研究,突出了其对肺癌研究产生重大影响的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
期刊最新文献
Association of single nucleotide polymorphisms rs7459185 of the HSPβ1 gene and the risk of hematological toxicity in lung cancer. Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database. Rearranged during transfection (RET) lung cancer - Update on targeted therapies. Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group. Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1